? We propose to extend our successful development of an agile spectral light source for light microscopy, funded through the NCI-IMAT initiative, into FDA trials. The SpectraLamp(tm) device enables the automated and quantitative analysis of double-immunostained samples in brightfield (non-fluorescence-based) microscopy, with particular utility for hematopathology applications. A clinically compelling area is the enumeration of malignant blasts in bone marrow biopsy specimens of patients with acute leukemias, myelodysplastic syndromes and chronic myleloproliferative diseases for the purpose of staging and evaluating therapeutic responses. Current methods are inadequate due to poor sampling (typical of bone marrow aspirates) or difficulty in identifying true blasts (bone marrow biopsies and single-color immunohistochemical phenotyping). Double-immunophenotyping permits largely unambiguous detection, but such labeling strategies are not supported by standard (non-multispectral) color imaging systems. To overcome this limitation, we will combine our multispectral imaging system with a high-speed slide-scanning platform that can scan an entire bone-marrow biopsy at high resolution in under 3 minutes. Machine-learning software tools and spectral imaging will identify blasts, combining morphology parameters and double or even triple immunophenotyping to ensure accuracy and precision. After blasts are identified, flow-cytometrylike software will present the data in histograms and other modalities, allowing the user to """"""""gate"""""""" on particular cellular populations and pull up panels of cell images for confirmation. ? ? Time-line: Final equipment-related tasks will be accomplished in the first year and preliminary testing of the instrumentation and software features will occur in the second year, as will development of qualified panels of immunoreagents and staining protocols (by DAKOCytomation). FDA-sanctioned clinical trials will be conducted in the third year, leading to submission of an application for a 510(k) clearance. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44CA088684-06
Application #
7096660
Study Section
Special Emphasis Panel (ZRG1-SBMI (11))
Program Officer
Rasooly, Avraham
Project Start
2000-09-30
Project End
2008-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
6
Fiscal Year
2006
Total Cost
$1,029,373
Indirect Cost
Name
Cambridge Research and Instrumentation
Department
Type
DUNS #
147950828
City
Woburn
State
MA
Country
United States
Zip Code
01801
Levenson, Richard M; Lynch, David T; Kobayashi, Hisataka et al. (2008) Multiplexing with multispectral imaging: from mice to microscopy. ILAR J 49:78-88
Levenson, Richard M; Mansfield, James R (2006) Multispectral imaging in biology and medicine: slices of life. Cytometry A 69:748-58
Taylor, C R; Levenson, R M (2006) Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. Histopathology 49:411-24
Levenson, Richard M (2006) Spectral imaging perspective on cytomics. Cytometry A 69:592-600
Angeletti, Cesar; Harvey, Neal R; Khomitch, Vitali et al. (2005) Detection of malignancy in cytology specimens using spectral-spatial analysis. Lab Invest 85:1555-64
Jaganath, Rajesh; Angeletti, Cesar; Levenson, Richard et al. (2004) Diagnostic classification of urothelial cells in urine cytology specimens using exclusively spectral information. Cancer 102:186-91